Precigen reports FY2024 net loss of $126M; FDA priority review for PRGN-2012 BLA

PRECIGEN, INC.

FDA accepted BLA for PRGN-2012 with priority review; PDUFA target date Aug 27, 2025.
Pivotal study: 51% complete response (no surgeries), durable beyond 12 months (median 24 months).
FY2024 net loss $126.2M ($0.47/share) vs $95.9M in 2023; revenue down 37% to $3.9M.
Cash, equivalents, investments $97.9M; runway extended into 2026 beyond potential launch.
Raised $87.5M in Dec 2024 from convertible preferred stock ($79M) and IP/royalty sale ($8.5M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.